CD274 and non-small cell lung carcinoma: ALI was significantly associated with ORR, DCR, and TOT in NSCLC patients treated with PD-L1 monotherapy (cohort A): for ALI >18 versus ALI ≤18, ORR was 36% versus 24% (P = 0.0080), DCR 65% versus 46% (P < 0.001), and the TOT HR = 0.52 (CI 0.41-0.65, P < 0.001, Table 3).